Table 1.
Unrelated Transplantations |
Matched Related Transplantations |
P Value | |
---|---|---|---|
No. of patients | 203 | 211 | |
Patient age, median (range) | 44.5 (18–69) | 48 (23–71) | .0233 |
Disease | .2132 | ||
AML | 80 (39%) | 75 (36%) | |
MDS | 21 (10%) | 26 (12%) | |
ALL | 30 (15%) | 19 (9%) | |
NHL | 32 (16%) | 46 (22%) | |
Other* | 40 (20%) | 45 (21%) | |
Conditioning | .4541 | ||
Bu/flu | 70 (34%) | 61 (29%) | |
Bu/flu/TBI+ | 38+(2) (20%) | 43+(1) (21%) | |
Flu/mel/TBI+ | 11+(3) (7%) | 13+(5) (9%) | |
R+/− BEAM | 19 (9%) | 30 (14%) | |
Other† | 60 (30%) | 58 (27%) | |
Donor/recipient sex | .0016 | ||
F/f | 33 (16%) | 48 (23%) | |
F/m | 35 (17%) | 55 (26%) | |
M/f | 58 (29%) | 42 (20%) | |
M/m | 77 (38%) | 66 (31%) | |
Donor/recipient CMV status | .1952 | ||
Neg/neg | 62 (31%) | 69 (33%) | |
Neg/pos | 65 (32%) | 48 (23%) | |
Pos/neg | 22 (11%) | 28 (13%) | |
Pos/pos | 54 (27%) | 66 (31%) | |
Donor age, median (range) | 36.5 (18–60) | 46.5 (18–75) | <.0001 |
CD 34+median (range), 106/kg | 7.28 (1.49–19.12) | 5.78 (2.12–14.05) | <.0001 |
HLA match | <.0001 | ||
8/8 | 136 (67%) | 194 (92%) | |
7/8 | 67 (33%) | 17 (8%) | |
Disease risk | .3217 | ||
Low | 75 (37%) | 88 (42%) | |
High | 128 (63%) | 123 (58%) | |
Stem cell source | .4960‡ | ||
PBSC | 198 (98%) | 208 (99%) | |
BM | 5 (2%) | 3 (1%) | |
No. of prior transplantations | .0521 | ||
0 | 193 (95%) | 190 (90%) | |
1 or more (auto) | 10 (5%) | 21 (10%) |
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; M, male; F, female; Bu, busulfan; mel, melphalan; BEAM, carmustine, etoposide, cytarabine and melphalan; TBI, total body irradiation; PBSC, peripheral blood stem cells; BM, bone marrow.
Other includes chronic myelogenous leukemia, MPD, multiple myeloma, chronic lymphatic leukemia, PLL, and Hodgkin disease.
Other includes VP16/TBI, CY/TBI, BAC, CY/FLU/TBI, CVB+(R), and BU/CY.
Fisher exact test. The others were chi-square test for the categorical variables.